Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Cash from Financing Activities data on file, last reported at $3.5 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $3.5 million, up 539.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.9 million (down 97.97% YoY), and the FY2025 annual result was $4.9 million, down 99.31% from the prior year.
• Cash from Financing Activities advanced to $3.5 million in Q1 2026 per JANX's latest filing, from $2.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $386.6 million in Q4 2024 and troughed at $1000.0 in Q1 2022.
• A 5-year average of $48.9 million and a median of $1.3 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 100.0% in 2022, then soared 157900.0% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $191000.0 in 2022, then surged by 335.08% to $831000.0 in 2023, then jumped by 46428.28% to $386.6 million in 2024, then slumped by 99.24% to $2.9 million in 2025, then increased by 20.41% to $3.5 million in 2026.
• Business Quant data shows JANX's Cash from Financing Activities at $3.5 million in Q1 2026, $2.9 million in Q4 2025, and $493000.0 in Q3 2025.